Posts With Tag Restricted Stock Units

Explore Ascendis Pharma A/S's February 2025 financial report detailing an $18.25M share repurchase program and $9M RSU net settlement, showcasing strategic capital management.

TORM plc's December 2024 Form 6-K reveals a capital increase via 7,468 Class A shares from RSU exercises. Details included in the December 18 press release.